Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?

Eli Lilly (LLY) will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, respectively.The strong sales performance of its FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound, helped Lilly deliver exceptionally strong results in the last report quarter. We expect the trend to continue in the third quarter.Tirzepatide is a dual GIP and GLP-1 receptor ...